The adult brain responds to focal infarction with proliferation of glial subpopulations. In addition, cells that express the immature neuronal marker doublecortin have been found consistently in the perileisonal zone. We investigated whether application of brainderived neurotrophic factor (BDNF) would influence this perilesional proliferative response. Photothrombotic infarcts were induced in the sensorimotor forelimb and hindlimb cortex of adult rats. Brain-derived neurotrophic factor or vehicle was continuously infused intraventricularly for 2 weeks after the infarct using osmotic minipumps. Proliferating cells were labeled by daily intraperitoneal injections of bromodeoxyuridine during the first 2 weeks and were quantified at days 14 and 42 using semiautomatic stereology. Triple immunofluorescence with antibodies against immature and mature neuronal and glial markers was used to identify the proliferating cell populations. On day 14 after intraventricular BNDF application, the numbers of doublecortin-positive cells were doubled in the perilesional zone. On day 42, BDNF-treated animals had a small number of mature neurons in these areas, whereas vehicle-treated controls did not. Behavioral analysis with a battery of sensorimotor tests revealed, however, that the alterations in the perilesional cellular response were not associated with an improved functional outcome.
INTRODUCTION
Focal ischemic brain injury induces a complex proliferative response of distinct glial (1, 2) and neuronal subpopulations (3Y6) in the perilesional zone. Proliferating glia mainly contribute to the formation of the scar, but little is known about the role of the proliferating neuronal progenitors that have been identified around such lesions. Increasing evidence indicates that newly generated neuroblasts migrate from the subventricular zone toward ischemic lesions (3Y9), but whether they give rise to new mature neurons is unclear. Migrating neuroblasts express the microtubule-associated protein doublecortin (DCX), which is transiently found in developing neurons (10Y13). Neither the origin nor the fate of these neuroblasts has been reliably determined. Nevertheless, several studies have described an increase of DCXexpressing neuroblasts (5, 14, 15) and, at least in part, the generation of mature neurons in areas surrounding ischemic infarcts (5, 16) .
To assess DCX-positive cells in the perilesional zone among the different proliferating glial subpopulations, we quantified the cellular response in the direct vicinity of small photochemically induced cortical infarcts stereologically and determined whether brain-derived neurotrophic factor (BDNF) treatment influenced these processes. Under physiological conditions, BDNF increases the numbers of newborn neuroblasts in the adult brain and promotes their maturation and integration into existing networks (17Y21). Furthermore, BDNF increases synaptogenesis and angiogenesis, thereby favoring sensorimotor recovery after focal infarction (22Y25). We demonstrate here that even low dosages of exogenous BDNF administered intraventricularly after an ischemic lesion results in significantly increased numbers of proliferating neuroblasts and facilitates the generation of mature neurons in the peri-infarct zone. Among glial subpopulations, BDNF only decreased microglial proliferation, whereas astrogliosis was not impaired. Based on a battery of sensorimotor functional tests, however, the BDNF-induced increase in perilesional neurogenesis was not correlated with a better behavioral performance.
MATERIALS AND METHODS

Induction of Photothrombotic Infarcts
The study was carried out on a total of 28 male Wistar rats (age: 12Y14 weeks; weight: 250Y300 g) and performed in accordance with the guidelines of the National Institutes of Health (revised 1987) . The experimental procedures were approved by the German Animal Care and Use Committee. All animals received photothrombotic cortical infarcts in the forelimb and hindlimb sensorimotor cortex using the method initially described by Watson et al (26) . The animals were anesthetized with 2.5% to 3.5% isoflurane (Baxter, Unterschleissheim, Germany) in a mixture of oxygen/nitrous oxide (30%/70%). Body temperature was kept constant throughout the surgery at 36.5-C. The scalp was opened with a short incision, and a fiberoptic bundle (3.0 Â 4.0 mm in diameter) connected to the cold light source (KL 1500; Schott, Jena, Germany) was positioned on the skull. The following stereotaxic coordinates were used: 0.0 mm anteroposterior relative to bregma and 2.0 mm right to the midline corresponding to the region of the forelimb and hindlimb sensorimotor cortex (27) . The beam had a light intensity of 15 W/cm 2 , and the color temperature was 3,200K. Immediately after the onset of 20-minute illumination, Rose Bengal (Sigma-Aldrich, Taufkirchen, Germany) (1.3 mg/100 mg body weight at a concentration of 10 mg/ml in 0.9% NaCl) was injected through a femoral vein catheter. All animals were housed in standard cages (4 rats per cage) under 12-hour light/ 12-hour dark conditions with free access to food and water.
Implantation of Osmotic Minipumps and Experimental Design
After induction of the focal cortical infarct, osmotic minipumps (Alzet 2002; Alza Scientific Products, Palo Alto, CA) were implanted at the time of surgery. To prevent an additional lesion, the minipump cannula was positioned within the photothrombotic infarction. A burr hole (diameter: 1.1 mm) was drilled into the skull at 0.3 mm posterior to bregma and 1.3 mm lateral to the midline, and the cannula of the osmotic minipump (Alzet Brain Infusion Kit 2; Alza Scientific Products) was then inserted up to a depth of 4.5 mm from the pial surface into the right lateral ventricle (Fig. 1) . Two experimental groups received either human recombinant BDNF (Sigma-Aldrich) (1 Kg/ml dissolved in 0.9% NaCl, n = 14) or vehicle (0.9% NaCl, n = 14) (Fig. 2) . Previous reports on the stability of BDNF demonstrated that this neurotrophin retains its full biological activity during (B) Coronal sections based on Nissl stain through the photothrombotic infarct (shaded area) with the localization of the intraventricular cannula at day 14 after surgery. (C) Diagram of a parasagittal section of the rat brain showing a lateral view of the photothrombotic infarct (shaded area), the perilesional zone surrounding the infarct (black), and the placement of the cannula in the right lateral ventricle. CC, corpus callosum; CTX, cortex; LV, lateral ventricle; OB, olfactory bulb; PT, photothrombotic stroke. FIGURE 2. Schematic illustration of the experimental design and sensorimotor testing protocol. (A) All animals received a photothrombotic stroke in the sensorimotor forelimb and hindlimb cortex and were allowed to survive for 14 or 42 days. Osmotic minipumps were implanted immediately after the infarct, and brain-derived neurotrophic factor (BDNF) (0.5 ng/hour) or vehicle (0.9% NaCl) was continuously applied for 14 days. To detect proliferating cells, all animals received daily intraperitoneal bromodeoxyuridine (BrdU)-injections at days postinfarct (DPI) 1 to 13. (B) A battery of sensorimotor tests was performed at different time points: limb-use asymmetry test and ladder rung walking test at days 1, 13, and 41 and tapered walking beam test at days 3, 13, and 41 after surgery.
osmotic minipump delivery at 37-C (28, 29) . The osmotic minipumps had a release rate of 12 Kl/day for 2 weeks corresponding to a daily dose of 12 ng BDNF (0.5 ng/hour) according to a previous study (17) . Before implantation, the pumps were activated for 1 hour in sterile saline at 37-C. After surgery, the animals were returned to their standard cages. To label proliferating cells, all animals received daily single intraperitoneal injections of bromodeoxyuridine (BrdU, 50 mg/kg; Sigma-Aldrich) from day 1 until day 13 postinfarct (DPI) (Fig. 2) . On DPI 14 (BDNF: n = 6; vehicle: n = 6) or DPI 42 (BDNF: n = 8; vehicle: n = 8), the animals were anesthetized with diethylether and perfused transcardially with 4% phosphate-buffered paraformaldehyde. The brains were removed, postfixed in 4% paraformaldehyde overnight, and cryoprotected in 30% sucrose for 48 hours. Sequential sections (40 Km) were cut with a freezing microtome and stored in a cryoprotectant tissue solution at j20-C.
Behavioral Testing
Sensorimotor function was assessed using 3 different behavioral tests: the limb-use asymmetry test at DPI 1, 13, and 41; the tapered beam walking test at DPI 3, 13, and 14; and the ladder rung walking test pretreated and at DPI 1, 13, and 41 ( Fig. 2B) .
The limb-use asymmetry test was performed to analyze the spontaneous vertical exploration movements of both forelimbs based on the method described by Schallert et al (30) . Rats were placed in a transparent glass-cylinder (diameter: 25 cm, height: 26 cm) and video recorded via 2 mirrors combined at an angle of 90 degrees placed behind the cylinder for 10 to 15 minutes to detect 12 forelimb rearing movements per trail. The independent or simultaneous use of the left or right paw was analyzed during vertical and horizontal movements along the cylinder wall of each forelimb. The number of the ipsilateral, contralateral, and bilateral forepaw wall contacts were analyzed, and the percentage of limb use was calculated as described in detail by Schallert et al (31) .
The ladder rung walking test was performed to investigate the forelimb and hindlimb use during skilled locomotor activity based on the method described by Metz and Whishaw (32) . The animals had to cross a horizontal ladder rung with walls of clear Plexiglas and metal rungs (diameter: 0.3 cm) ordered in an irregular pattern (variety of 0.5Y5 cm). Five crossings per testing session were recorded using a digital camera placed in a lateral position at a slight ventral angle. The performance of forelimb and hindlimb placing was then evaluated using a score described in detail by Metz and Whishaw, and the percentage of the different scores was calculated for each limb (32) .
In addition, the tapered beam-walking test was used to further analyze limb use during skilled locomotor activity based on the method described by Schallert et al (30) . In this test, the rats had to cross an apparatus consisting of a tapered beam with under hanging ledges on each side to permit foot faults without falling. A mirror behind the walking beam allows the detection of each limb. Five crossings per testing session were recorded using a digital camera. The number of foot faults defined as steps onto the ledge or side touches of the beam was counted, and the fault ratio (number of foot faults/number of total steps) was calculated for each forelimb and hindlimb (33) .
The limb-use asymmetry test and the tapered beamwalking test were performed without baseline testing of the animals. A detailed baseline performance was only determined for the ladder rung walking test, which shows the highest sensitivity to detect fine-motor disturbances. All behavioral tests were evaluated off-line using frame-by-frame analysis in slow motion by an independent investigator blinded to the experimental conditions.
Volumetry
Using a charge-coupled device camera and National Institutes of Health Image software, the area of the cortical infarct as well as that of both hemispheres (mm 2 ) was measured by tracing these regions on the computer screen. The infarct area was quantified on every 8th section (40 Km) and the global brain volume on every 12th section. Volumes (mm 3 ) were determined by integration of the appropriate region with the section interval thickness (infarct volume, 320 Km; global brain, 480 Km).
Immunocytochemistry
Immunocytochemistry for BrdU was performed to quantify the perilesional proliferative response in the different experimental groups. Free-floating sections were treated with 0.6% H 2 O 2 in Tris-buffered saline (pH 7.5) for 30 minutes to block endogenous peroxidase. After washing, sections were incubated in 2 N HCl at 37-C for 30 minutes, rinsed in boric acid (pH 8.5) for 10 minutes, and incubated after several rinses in Tris-buffered saline (containing 0.25% Triton X-100) overnight at 4-C in primary rat monoclonal anti-BrdU (1:500) containing 3% normal donkey serum and 0.1% Triton X-100 in Tris-buffered saline. Sections were then rinsed in Tris-buffered saline and blocking serum for 30 minutes and incubated in the secondary antibody (biotinylated donkey anti-rat antisera, 1:500; Jackson Immunoresearch, West Grove, PA) for 2 hours at room temperature. After rising, the slices were treated in avidin-biotinperoxidase complex (Vector Laboratories, Burlingame, CA) for 60 minutes. Finally, the sections were transferred into a solution of 3.3-diaminobenzidine (0.25 mg/ml; SigmaAldrich, Munich, Germany) containing 0.01% H 2 O 2 for peroxidase detection. Sections were thoroughly washed, mounted, and coverslipped (Entellan; Merck, Darmstadt, Germany).
For further phenotype analysis of the BrdU-positive cells, double-and triple-immunofluorescence staining was performed. The brains were treated in the same way as described for the peroxidase staining. Section were incubated for 24 hours with the primary antibodies rat anti-BrdU (1:500; Immunologicals Direct-Oxford Biotechnology, Oxfordshire, UK), mouse anti-NeuN (1:500; Chemicon, Temecula, CA), and mouse anti-Hu for mature neurons (1:500; Santa Cruz Biotechnology, Santa Cruz, CA); goat anti-DCX for neuronal precursors (1:500; Santa Cruz), guinea pig antiYglial fibrillary acidic protein (GFAP) (1:1000; Advanced Immunochemistry, Los Angeles, CA), and rabbit anti-S100Q for astrocytes (1:2500; Swant, Bellinzona, Switzerland); and mouse anti-CD68 clone ED1 for macrophages and microglia (1:500; Serotec, Oxford, UK). Immunofluorescent double and triple labeling was performed using the following secondary antibodies: rhodamine anti-rat (1:250; Dianova, Hamburg, Germany), CY5 anti-mouse (1:250; Dianova), CY5 antirabbit (1:250; Dianova), Alexa Fluor 488 anti-rabbit (1:250; Molecular Probes, Leiden, Netherlands), Alexa Fluor 488 antiYguinea pig (1:250; Molecular Probes), and Alexa Fluor 488 anti-goat (1:250; Molecular Probes).
To assess apoptotic cell death, the terminal deoxynucleotidyl transferaseYmediated dUTP in situ nick endlabeling (TUNEL) method was used according to the protocol supplied by the manufacturer (In Situ Cell Death Detection Kit, TMR red; Roche Diagnostics, Mannheim, Germany).
Stereology and Quantification
The optical fractionator technique (34) was used to assess the total numbers of BrdU-positive cells in the perilesional area (StereoInvestigator, MicroBrightField, Colchester, VT) (Fig. 3) . The quantification of the newly generated cells was analyzed on every 12th section from 2 mm anterior to bregma and 2 mm posterior to bregma of the stereotaxic atlas by Paxinos (27) . The perilesional zone was defined as a 500-Km-wide cortical zone directly surrounding the infarct. The following analytic parameters were used: a 60 Â 60-Km counting frame, a 15-Km dissector cube height, and a 95 Â 145-Km grid size. Section thicknesses were measured, and appropriate guard zones at the top and the bottom of the section were defined to avoid oversampling. With the aid of a 63Â objective, the BrdU-positive cells (peroxidase method) were counted. A cell was counted when the cell soma intersected the uppermost focal plane (exclusion plane). The perilesional area reference volume was determined by adding the traced perilesional area for each section multiplied by the distance between sections sampled. The total number of BrdU-labeled cells in the perilesional zone was then related to a sectional volume of 1 mm 3 . Phenotypes of BrdU-positive cells were analyzed by confocal laser scanning microscopy (LSM Meta 510; Zeiss, Germany). For each animal, the colocalization of 90 to 100 BrdU-positive cells was defined using a Z-scan to verify a clear colabeling of the BrdU-stained nucleus with cellspecific markers. The absolute number of colabeled cells was calculated per animal by multiplying the absolute number of BrdU-positive cells with the percentage of the phenotype of interest. 
Statistical Analysis
For statistical analysis, we first tested for normal distribution using the Shapiro-Wilk test. Statistical significance differences of cell counts and phenotypes were tested with an unpaired 2-tailed t-test. Differences in the sensorimotor behavioral tests were assessed using the Mann-Whitney Utest. All numerical analyses were performed using SPSS for Windows 11.5 (Standard Version). All cell counts and phenotype analysis are expressed as mean T SD; the behavioral data are given as mean T SEM. A level of p G 0.05 was considered statistically significant.
RESULTS
All animals in the experimental groups had typical photothrombotic infarcts. The lesions injured all cortical layers and involved the complete sensorimotor forelimb and hindlimb regions. Because the cannula of the osmotic minipump was implanted directly through the cortical lesion, the corpus callosum was lesioned in all animals. Furthermore, some animals (n = 3) demonstrated a slightly increased size of the ventricles, but no structural alterations of the ventricle walls. Osmotic minipumps showed no residua of the drug solution at the end of the experiments. 
Cellular Proliferation and Differentiation in the Perilesional Zone
Quantification of BrdU-positive cells in the perilesional zone revealed no major alterations in cellular proliferation in BDNF-treated animals (Fig. 3B ). Brain-derived neurotrophic factor only slightly increased the number of BrdU-positive cells up to 25% (p = 0.145) at DPI 14 compared with the vehicle group reaching no statistical significance. Related to the cell counts at DPI 14, only 57% ( p = 0.014) of the BrdUpositive cells survived at DPI 42 in the vehicle group, whereas the BDNF group showed a survival of 70% ( p = 0.088). At DPI 42, the number of BrdU-positive was highest in the BDNF group compared with the vehicle group (p = 0.08). Quantification of terminal deoxynucleotidyl transferaseY mediated dUTP in situ nick end-labelingYpositive cells revealed no significant differences in numbers of apoptotic cells between the BDNF and vehicle group at DPI 14 (BDNF group: 169 T 75/mm 3 , vehicle group: 498 T 482/mm 3 ) (Fig. 3D) . However, intraventricular application of BDNF differentially influenced the phenotypic differentiation of BrdUpositive cells at DPI 14 and 42 (Fig. 4) . Immunocytochemistry with antibodies against BrdU and DCX revealed a significant increase in number of BrdU-DCXYpositive immature neurons at DPI 14 compared with the vehicle group ( p = 0.005) (Fig. 4E) . At DPI 42, a small number of BrdU-NeuNY positive cells (483 T 167 cells/mm 3 ) was found in the BDNFtreated group, whereas no new neurons were found in the vehicle group (Fig. 4E ). Additional colabeling with the mature marker Hu further demonstrated 3% T 1% BrdUHu-positive cells only in the BDNF group, indicating that at least a small number of DCX-positive neuroblasts differentiate into mature neurons. Analysis of the spatial distribution of these newly generated neurons in 4 BDNF-treated animals demonstrated that these cells were equally distributed in the perilesional zone without any regional or laminar preference (Fig. 4F) .
The total numbers of GFAP-BrdUYpositive astrocytes did not significantly differ between the BDNF and vehicle group ( p = 0.076) at DPI 14 (Fig. 5A) . However, the percentage of the BrdU-GFAPYpositive astrocytes related to the total numbers of BrdU-positive cells was significantly decreased in the BDNF group (21% T 7%, p = 0.003) compared with the vehicle group (35% T 9%). Until DPI 42, the number of BrdU-GFAPYpositive cells was nearly halved in both groups with no significant differences between vehicle-and BDNF-treated animals (p = 0.609). Additional immunocytochemistry with the astrocytic marker S100A confirmed these findings and showed no differences at either DPI 14 or 42 between the experimental groups (Fig. 5B) .
Further immunocytochemical analysis of BrdU-positive microglia/macrophages in the perilesional zone demonstrated a significant reduction of BrdU-CD68Ypositive cells in BDNFtreated animals (BDNF group: p = 0.021) compared with the vehicle group at DPI 14. The BDNF-induced reduction of newly generated microglia/macrophages was absent at DPI 42 (p = 0.655) (Fig. 5C) .
Taken together, these immunocytochemical findings indicate that intraventricular infusion of BDNF after photothrombotic lesions significantly increase the proliferation of immature neurons, which, in a very small number of cells, differentiate into mature neurons. Furthermore, these data demonstrate that administration of BDNF diminishes the proliferation of microglia/macrophages in the perilesional zone.
Sensorimotor Performance
To analyze whether these cellular alterations correlate with the functional outcome, a battery of sensorimotor tests was performed. Using the limb-use asymmetry test, the ladder rung walking test, and the tapered beam-walking test, no significant differences between BDNF-and vehicletreated animals were observed (Fig. 6) .
The limb-use asymmetry test revealed a significant functional deficit of the affected forelimb in all animals. Both the vehicle and the BDNF group showed a significantly reduced use of the contralesional forelimb during exploratory movements on the wall of the glass cylinder at day 1 after the infarct (vehicle: impaired 15% T 2%, unimpaired 36% T 5%, p = 0.006; BDNF: impaired 16% T 2%, unimpaired 41% T 8%, p = 0.035). However, comparison of the use of the impaired, unimpaired, or both forelimbs detected no differences between BDNF-and vehicle-treated animals at DPI 1, 13, and 41 (Fig. 6A) . The tapered beam-walking test demonstrated a high number of foot-faults of the affected hind limb at DPI 3 in all animals (BDNF: 91% T 5%; vehicle: 86% T 6%), whereas the contralesional forelimb was only slightly affected (BDNF: 2%4 T 6%; vehicle: 14% T 2%). The number of foot faults decreased until day 41 (BDNF: 18% T 6%; vehicle: 41% T 9%), but again no significant differences could be detected between the experimental groups (Fig. 6B) . Finally, we used the ladder rung walking test to analyze forelimb and hind limb function during skilled locomotor activity. This test demonstrated a significant deficit of contralesional forelimb and hindlimb function, which still FIGURE 5. Immunocytochemical quantification of newly generated glial fibrillary acidic protein (GFAP)-and S100A-positive astrocytes and CD68-positive microglia in the perilesional zone from confocal images of double-or triple-labeled sections. (A) Bromodeoxyuridine (BrdU) (red) and GFAP (green); (B) BrdU (red) and S100 (blue); (C) BrdU (red) and CD68 (green). To analyze the colocalization of these different markers, we defined the immunohistochemical phenotype of BrdU-positive cells using Z-stack scans. Scale bars: 10 Km. (A, B) Quantification of the BrdU-GFAP-positive and BrdU-S100-positive astrocytes in the perilesional zone at days 14 and 42 after infarct induction. The total numbers of activated astrocytes did not significantly differ between the brain-derived neurotrophic factor (BDNF) and control groups at DPI 14 and 42. Quantification of the BrdUCD68Ypositive microglia in the perilesional zone at DPI 14 and 42 is also shown in C. Total numbers of activated microglia were significantly reduced after BDNF application at DPI 14. Bars represent mean T SD. Asterisks indicate significant differences (p G 0.05).
persisted at DPI 41. Significant differences between the vehicle and BDNF groups were not detected (Fig. 6C) .
DISCUSSION
This study demonstrates that focal cortical infarcts induce the proliferation of a major population of DCXpositive neuroblasts in the perilesional zone 2 weeks after the infarct, but none of these proliferating neuroblasts differentiate into mature neurons in the chronic phase, 6 weeks after the infarct. Intraventricular infusion of BDNF during the first 2 weeks after the infarct significantly increased the number of DCX-positive neuroblasts and provoked the generation of new neurons that expressed mature markers. The photographs indicate distinct foot fault scores described in detail by Metz and Whishaw (32) . Dots between the data columns indicate baseline performance. Note that the percentage of nearly perfect limb placing (score 6) was strongly reduced at DPI 41 compared to baseline performance indicating a long-lasting deficit of the contralesional forelimb and hindlimb. Significant differences between the vehicle and BDNF groups overall were not detected. Data represent mean T SEM. Asterisks indicate significant differences at specific time points (p G 0.05).
Not only the neuronal subpopulations but also the proliferation of microglia and macrophages was influenced by BDNF application in the perilesional zone. Brain-derived neurotrophic factor reduced the number of newly generated microglia/macrophages 2 weeks after the lesion, whereas S100-and GFAP-expressing astrocytes were not significantly influenced. Behavioral sensorimotor assessment further showed that these BDNF-induced cellular alterations did not correlate with a better functional recovery.
Proliferation of DCX-Positive Neuroblasts in the Perilesional Zone
The finding of abundant newly generated DCX-positive neuroblasts in the perilesional area is in accordance with previous studies in different models of focal brain injury (3, 4) . Doublecortin has been described as a selective marker of migrating neuroblasts and immature neurons in the neurogenic regions of the adult brain (35Y38). Doublecortin-positive cells have also been found in the neocortex where they show no colabeling with astrocyte or mature oligodendrocyte markers (39Y41). After frontoparietal cortex lesions in adult rats, Gotts and Chesselet (14) described an increase of neuroblasts 5 days after surgery in the subventricular zone, the rostral migratory stream, the corpus callosum, and the perilesional zone; DCXpositive cells have also been found in the neocortex and corpus callosum after an ischemic lesion (6) . It is widely accepted that newly generated neuroblasts migrate from the subventricular zone into the damaged striatum and give rise to new neurons in the ischemic penumbra after middle cerebral artery occlusion (4). Ohab and colleagues (5) showed a migration of DCX-positive cells from the subventricular zone toward the peri-infarct zone of cortical infarcts in the sensorimotor barrel field cortex where these cells differentiate into new neurons. Although several studies provide some evidence for a migration of neuroblasts from the subventricular zone toward the lesion, it is also conceivable that quiescent precursor cells in the neocortex contribute to this population of DCX-positive neuroblasts in the perilesional zone. The existence of multipotent neural precursors in the neocortex possessing the potential to differentiate into a neuronal lineage has been demonstrated in different studies (42, 43) . Therefore, it is currently difficult to determine the exact origin of the DCX-positive cells in the perilesional zone of infarcts in the present study. At DPI 42, however, no mature BrdU-positive neurons were found in the vehicle-treated animals, indicating that the DCX-positive neuroblasts did not differentiate into neurons. The question whether neurogenesis is a general phenomenon in the perilesional neocortex is still unresolved. Several studies demonstrated a small number of new neurons after ischemia or neuronal death in the neocortex (5, 16, 44, 45) . In contrast, others failed to detect cortical neurogenesis after focal ischemia (3).
BDNF-Induced Neurogenesis in the Peri-infarct Zone
Our study demonstrated that intraventricular application of low dosages of BDNF increase the number of newly generated neuroblasts in the perilesional zone of photothrombotic infarcts. Exogenous BDNF has been shown to enhance the proliferation of neural stem cells, to increase the differentiation and survival of neurons, and to promote neurite growth in several studies under physiological conditions (17) . Pencea and colleagues (46) described an increase of neuroblasts in the rostral migratory stream after intraventricular BDNF application and an increased neurogenesis in the olfactory bulb, striatum, and thalamus. As a member of the neurotrophin family, BDNF is found in widespread areas of the brain, acting through the tyrosine kinase receptor B (47) . Neurons, as well as astrocytes, express this receptor and respond to BDNF by changing their cellular calcium and glutamate levels (48) . Under ischemic conditions, BDNF levels were upregulated (49), correlating with the prevention of neuronal death and reduction of infarct size (22) . Exogenous administration of BDNF further decreased neuronal necrosis after ischemic insults (50, 51) . These protective effects of BDNF may be mediated by stabilization of neuronal calcium homeostasis, which inhibited the apoptotic cascades (52) . In the present study, no changes in number of apoptotic cells were identified. Nevertheless, the effects of BDNF on plasticity in the adult brain are dependent on the dosage, period of administration, and the application form. A much higher intraventricular dosage of BDNF (2.1 Kg/day) reduced the size of photothrombotic infarcts (53) , whereas a lower dosage of BDNF as used in the present study (12 ng/ day) (17) did not influence the infarct volume. However, even the low dosage of BDNF used here increased the number of neuroblasts in the perilesional zone and induced the generation of new neurons. Whether these few new neurons integrate into the existing neuronal networks has to be studied further; the underlying mechanisms are also unclear.
BDNF-Induced Reduction of Microglial Proliferation
This study demonstrated that BDNF infusion significantly reduced the generation of microglia and macrophages in the perilesional zone 2 weeks after the infarct. Kiprinova et al previously analyzed the effects of intraventricular infusion of BDNF using osmotic minipumps at day 7 after global ischemia and demonstrated that macrophage infiltration, as well as neuronal death, was inhibited by the application of BDNF (54) . The underlying mechanisms of these protective effects are unclear. In vitro studies provide evidence that BDNF inhibits the major histocompatibility complex class II, which is expressed by microglia (55) and might be involved in the activation of microglia after ischemia. Furthermore, BDNF application favors cell survival by inhibiting the release of toxic radicals from activated microglia (54) . It is conceivable that this reduction of the microglial perilesional response contributes to neurogenesis, but detailed analysis of the underlying mechanisms is needed.
Sensorimotor Recovery
Our study further indicates that the BDNF-induced alterations in the perilesional cellular response do not correlate with a better functional recovery in a battery of sensorimotor tests that have been shown to reveal longlasting behavioral deficits when the forelimb and/or hindlimb cortex was photochemically damaged (56) . Several studies focused on the effects of BDNF after ischemic and traumatic neuronal injury, but an improved functional outcome was only observed after systemic application of BDNF (23) . Using the same model of photothrombotic infarcts we used, Schäbitz et al (23) described a better motor performance in the rotarod test, the beam balance test, and neurological score when BDNF was applied intravenously during the first days after infarct induction. Joosten and Houweling (57) further demonstrated that systemic application of BDNF improved locomotor recovery in a model of spinal cord transection. However, both studies systemically applied high dosages of BDNF that have been shown to promote angiogenesis not only in the CNS but also in the cardiac and skeletal musculature (24, 58Y61). These peripheral effects might at least partially contribute to the better performances in the sensorimotor tasks. In accordance with our findings, Blaha and colleagues (62) detected no functional improvement after traumatic brain injury when BDNF was applied intraventricularly at high and low dosages using osmotic minipumps. Given the small numbers of new neurons we found in the perilesional zone, it seems unlikely that these cellular alterations contribute to a better functional performance.
In conclusion, our data demonstrate that intraventricular application of low dosages of BDNF after ischemic cortical infarcts increases the numbers of newly generated DCX-positive neuroblasts and induces the generation of new neurons in the perilesional cortex. Additional studies are needed to elucidate the role of this major population of DCXpositive cells that transiently appear in the perilesional zone.
